Baker Danial E
Washington State University, USA.
Hosp Pharm. 2017 May;52(5):374-380. doi: 10.1177/0018578717715383. Epub 2017 May 1.
Each month, subscribers to receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of publishes selected reviews in this column. For more information about , contact Wolters Kluwer customer service at 866-397-3433. The May 2017 monograph topics are brodalumab, etelcalcetide, guselkumab, ribociclib, and sirukumab. The MUE is on ribociclib.
每月，订阅者会收到5至6篇关于新发布或处于3期临床试验后期阶段药物的详细专题论文。这些专题论文面向药学与治疗学委员会。订阅者还会每月收到关于对议程以及药房/护理在职培训有用药物的1页摘要专题论文。每月还会提供一份全面的目标药物利用评估/用药评估（DUE/MUE）。订阅后，专题论文可供订阅者在线获取。专题论文可进行定制以满足机构的需求。通过合作，出版方会在本专栏发表精选评论。如需了解更多关于……的信息，请致电866 - 397 - 3433联系威科集团客服。2017年5月的专题论文主题包括布罗达单抗、依特卡肽、古塞库单抗、瑞博西尼和司库奇尤单抗。用药评估针对瑞博西尼。
